Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 218 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Food Effect cohort Clear all

Conditions: Chronic Kidney Injury
Interventions: CXA-10, CXA-10 placebo; Drug
Lead sponsor: Complexa, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Healthy Volunteers
Interventions: E2086, Placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: BPN-14967, Placebo; Drug
Lead sponsor: Belite Bio, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer Disease, Healthy Volunteers
Interventions: TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 179 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cancer
Interventions: Regimen A, Regimen B, Regimen C, Regimen D; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 4
States / cities: Scottsdale, Arizona • Detroit, Michigan • Nashville, Tennessee + 1 more

Conditions: Healthy
Interventions: RDEA3170, 10 mg, RDEA3170, 2.5 mg, RDEA3170, 5 mg; Drug
Lead sponsor: Ardea Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteers
Interventions: TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obesity
Interventions: AMG 786, Placebo; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Tustin, California • Aventura, Florida • Miami, Florida

Conditions: Healthy
Interventions: LY3866288; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Advanced Solid Tumors
Interventions: Tesetaxel, Itraconazole, Rifampin; Drug
Lead sponsor: Odonate Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Dallas, Texas • San Antonio, Texas

Conditions: Solid Tumor
Interventions: 7HP349 Single Ascending Dose, 7HP349 Multiple Ascending Dose, Placebo Single Ascending Dose, Placebo Multiple Ascending Dose, 7HP349 Food Effect; Drug
Lead sponsor: 7 Hills Pharma, LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Nonalcoholic Steatohepatitis (NASH)
Interventions: Cilofexor, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Volunteers
Interventions: Cohort 1: Lubiprostone Capsule, Fasted, Cohort 1: Lubiprostone Sprinkle Formulation, Fasted, Cohort 2: Lubiprostone Sprinkle Formulation, Fed, Cohort 2: Lubiprostone Sprinkle Formulation, Fasted; Drug
Lead sponsor: Sucampo Pharma Americas, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Lower Urinary Tract Symptoms
Interventions: Observational, Observational Controls, Central Sensitization, Physical Activity and Sleep Tracker, Physical Activity and Sleep Tracker Controls, Organ-Based, Qualitative Assessment of Patients with Urinary Urgency; Other
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 18 Years and older
Enrollment: 1,030 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Chicago, Illinois • Iowa City, Iowa • Ann Arbor, Michigan + 3 more

Conditions: Healthy
Interventions: TML-6 Granules, Placebo; Drug
Lead sponsor: Merry Life Biomedical Co., Ltd.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy
Interventions: PF-03382792 Cohort 1, PF-03382792 Cohort 2, PF-03382792, Food Effect cohort, CSF cohort; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes Mellitus
Interventions: XW014, Placebo; Drug
Lead sponsor: Sciwind Biosciences USA Co., Ltd.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 127 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 3
States / cities: Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: CTN XR (TBM), CTN SR, CTN XR (Clin); Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 174 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 2
States / cities: Lenexa, Kansas • Millcreek, Utah

Conditions: Healthy Volunteers
Interventions: MF-300 SAD, Placebo, MF-300 Food Effect, MF-300 MAD; Drug
Lead sponsor: Epirium Bio Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 2
States / cities: Marlton, New Jersey • Austin, Texas

Conditions: Healthy Volunteer
Interventions: Genz-682452, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 63 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
Interventions: CK-3773274 - Granules in Capsule, Placebo - Granules in Capsule, CK-3773274 - Tablets; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 114 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Obese, Overweight, Healthy
Interventions: LB64640, Placebo; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions: AVZO-021, Fulvestrant, Letrozole, AVZO-023; Drug
Lead sponsor: Avenzo Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 380 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 16
States / cities: Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more

Conditions: Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions: VLS-1488; Drug
Lead sponsor: Volastra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more

Search by objective public record fields.

Oral CXA-10 Study in Healthy Volunteers

A Study of E2086 in Healthy Adult Participants

Safety and Tolerability of Escalating Doses of BPN-14967 in Healthy Adults

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor

RDEA3170 Tablet and Capsule Bioavailability Study

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

Single and Multiple Ascending Dose Study to Evaluate AMG 786 in Healthy Participants and Participants With Obesity

A Study of LY3866288 in Healthy Participants

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

LURN: Urinary Urgency Phenotyping Protocol

A Phase 1 Safety and Tolerability Study of TML-6 in Healthy and Elderly Volunteers for Alzheimer's Disease Treatment

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)

A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels

Single and Multiple Ascending Dosing Administration of MF-300 in Healthy Participants

Safety, Tolerability and Pharmacokinetics of Genz-682452 in Healthy Men

A Single and Multiple Ascending Dose Study of CK-3773274 in Healthy Adult Subjects

A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer